2021
DOI: 10.1208/s12249-020-01891-x
|View full text |Cite
|
Sign up to set email alerts
|

Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 62 publications
0
1
0
Order By: Relevance
“…To date, only one study has regarded preclinical investigations [61]. The anticancer agent lapatinib, a tyrosine kinase inhibitor, has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer.…”
Section: Case Studies On Oro-dispersible Mts Obtained By Compression ...mentioning
confidence: 99%
“…To date, only one study has regarded preclinical investigations [61]. The anticancer agent lapatinib, a tyrosine kinase inhibitor, has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer.…”
Section: Case Studies On Oro-dispersible Mts Obtained By Compression ...mentioning
confidence: 99%